SGLT2抑制剂在心房颤动发生中作用的研究进展

Research progress of SGLT2 inhibitor in the occurrence of atrial fibrillation

糖尿病及其并发症与心房颤动(AF)发生密切相关。钠-葡萄糖协同转运蛋白2抑制剂(SGLT2i)作为一种新型降糖药,通过抑制钠-葡萄糖协同转运蛋白2(SGLT2)受体而降低肾糖阈,促进尿糖排泄,进而达到降糖作用。SGLT2i除降糖外,还具有降血压、减轻体质量、降血尿酸、减轻蛋白尿等一系列有益的作用。SGLT2i不仅能够降低心血管疾病死亡率和心力衰竭发生风险,而且越来越多的证据表明SGLT2i在减少AF发生中发挥重要作用。总结归纳了SGLT2i对T2DM患者AF发生的影响及其作用机制,为AF防治提供新方向。

Diabetes and its complications are closely related to the high incidence rate of atrial fibrillation(AF).Sodium-glucose cotransporter-2 inhibitor(SGLT2i),as a new type of hypoglycemic drugs,can reduce the renal glucose threshold by inhibiting SGLT2 receptor and ultimately achieve the hypoglycemic effect by promoting urine glucose excretion.In addition to the hypoglycemic effect,SGLT2i also has a series of beneficial effects such as reducing blood pressure,reducing body weight,lowering blood uric acid and reducing proteinuria.SGLT2i can not only reduce the risk of cardiovascular death and heart failure,but also more and more evidence shows that SGLT2i plays an important role in reducing AF occurrence.This paper summarizes the potential role of SGLT2i in AF,and its related mechanisms,which provides a new way for the prevention and treatment of AF.